Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...
Blog Post
March 14, 2023
On Wednesday March 8, the Center for Global Development hosted an event with Andrew Mitchell, Minister of State for Development and Africa of the United Kingdom, as part of our series of conversations and work on the future of development. The Minister spoke about the role the UK is playing today, t...
Blog Post
February 20, 2023
On Sunday February 19th, the 36th Assembly of Heads of State and Government of the African Union elected Dr Jean Kaseya, a public health physician from the Democratic Republic of Congo, as the new Director General of the Africa Centres for Disease Control and Prevention (Africa CDC). Dr Kaseya will ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...